- Home
- CBOE vs WAT Comparison
CBOE vs WAT Comparison
Compare CBOE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBOE | WAT |
|---|---|---|
| Founded | 1973 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 23.0B |
| IPO Year | 2010 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CBOE | WAT |
|---|---|---|
| Price | $246.08 | $385.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 15 |
| Target Price | $244.64 | ★ $388.67 |
| AVG Volume (30 Days) | ★ 649.7K | 544.8K |
| Earning Date | 10-31-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 26.68 | 3.82 |
| EPS | 9.30 | ★ 10.88 |
| Revenue | ★ $4,617,800,000.00 | $3,105,638,000.00 |
| Revenue This Year | N/A | $7.96 |
| Revenue Next Year | $5.52 | $6.32 |
| P/E Ratio | ★ $27.21 | $35.43 |
| Revenue Growth | ★ 16.74 | 6.90 |
| 52 Week Low | $187.30 | $275.05 |
| 52 Week High | $262.98 | $423.56 |
Technical Indicators
Market Signals| Indicator | CBOE | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 49.93 |
| Support Level | $247.68 | $385.08 |
| Resistance Level | $254.52 | $397.55 |
| Average True Range (ATR) | 4.37 | 9.33 |
| MACD | -1.28 | -3.46 |
| Stochastic Oscillator | 8.86 | 12.11 |
Price Performance
Historical ComparisonAbout CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.